Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia

Clinical Cancer Research

Volumn 19, Issue 12, 2013, Pages 3130-3142

  Lionetti, Marta ^a   Musto, Pellegrino ^b   Di Martino, Maria Teresa ^e   Fabris, Sonia ^a   Agnelli, Luca ^a   Todoerti, Katia ^c   Tuana, Giacomo ^a   Mosca, Laura ^a   Cantafio, Maria E Gallo ^e   Grieco, Vitina ^d   Bianchino, Gabriella ^d   D'Auria, Fiorella ^d   Statuto, Teodora ^d   Mazzoccoli, Carmela ^c   De Luca, Luciana ^c   Petrucci, Maria Teresa ^f   Offidani, Massimo ^h   Raimondo, Francesco Di ⁱ   Falcone, Antonietta ^j   Caravita, Tommaso ^g   Omede, Paola ^k   Morabito, Fortunato ^l   Tassone, Pierfrancesco ^e   Boccadoro, Mario ^k   Palumbo, Antonio ^k   Neri, Antonino ^a   more..

^a UNIVERSITY OF MILAN   (Italy)

^b Department of Onco Hematology ^*  (Italy)

^c Laboratory of Pre Clinical and Translational Research   (Italy)

^d REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^e UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g UNIVERSITY OF ROME TOR VERGATA   (Italy)

^h OSPEDALI RIUNITI   (Italy)

ⁱ UNIVERSITY OF CATANIA   (Italy)

^j CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^k UNIVERSITY OF TURIN   (Italy)

^l Azienda Ospedaliera di Cosenza   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 106B; MICRORNA 146A; MICRORNA 181A; MICRORNA 181B; MICRORNA 22; MICRORNA 330 3P; MICRORNA 497; MICRORNA 92A; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; BONE MARROW; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MULTIPLE MYELOMA; MYELOMA CELL; NUCLEOTIDE SEQUENCE; PLASMA CELL; PLASMA CELL LEUKEMIA; PRIMARY PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION;

EID: 84879476643     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2043     Document Type: Article

References (51)

1. Albarracin F, Fonseca R. Plasma cell leukemia. Blood Rev 2011;25: 107-12.
2. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-57.
3. Musto P, Pagano L, Petrucci MT, Morabito F, Caravita T, Di Raimondo F, et al. Primary plasma cell leukemia in the era of new drugs: has something changed? Crit Rev Oncol Hematol 2012;82:141-9.
4. van de Donk NW, Lokhorst HM, Anderson KC, Richardson PG. How I treat plasma cell leukemia. Blood 2012;120:2376-89.
5. Chiecchio L, Dagrada GP, White HE, Towsend MR, Protheroe RK, Cheung KL, et al. Frequent upregulation of MYC in plasma cell leukemia. Genes Chromosomes Cancer 2009;48:624-36.
6. Tiedemann RE, Gonzalez-Paz N, Kyle RA, Santana-Davila R, Price-Troska T, Van Wier SA, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia 2008;22:1044-52.
7. Avet-Loiseau H, Roussel M, Campion L, Leleu X, Marit G, Jardel H, et al. Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience. Leukemia 2012;26:158-9.
8. Avet-Loiseau H, Daviet A, Brigaudeau C, Callet-Bauchu E, Terre C, Lafage-Pochitaloff M, et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique. Blood 2001;97:822-5.
9. Garcia-Sanz R, Orfao A, Gonzalez M, Tabernero MD, Blade J, Moro MJ, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 1999;93:1032-7.
10. Chang H, Qi X, Yeung J, Reece D, Xu W, Patterson B. Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia. Leuk Res 2009;33:259-62.
11. Usmani SZ, Nair B, Qu P, Hansen E, Zhang Q, Petty N, et al. Primary plasma cell leukemia: clinical and laboratory presentation, geneexpression profiling and clinical outcome with Total Therapy protocols. Leukemia 2012;26:2389-405.
12. Lionetti M, Agnelli L, Lombardi L, Neri A. MicroRNAs in the pathobiology of multiple myeloma. Curr Cancer Drug Targets 2012;12:823-37.
13. Musto P, D'Auria F, Petrucci MT, Levi A, Cascavilla N, Falcone A, et al. Final results of a phase II study evaluating lenalidomide in combination with low dose dexamethasone as first line therapy for primary plasma cell leukemia. Blood 2011;118:2925.
14. Bird JM, Owen RG, D'Sa S, Snowden JA, Pratt G, Ashcroft J, et al. Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 2011;154:32-75.
15. Mosca L, Musto P, Todoerti K, Barbieri M, Agnelli L, Fabris S, et al. Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles. Am J Hematol 2013;88:16-23.
16. Lionetti M, Biasiolo M, Agnelli L, Todoerti K, Mosca L, Fabris S, et al. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 2009;114:e20-e26.
17. Sawyer JR. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genet 2011;204:3-12.
18. Zhou Y, Chen L, Barlogie B, Stephens O, Wu X, Williams DR, et al. Highrisk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc Natl Acad Sci U S A 2010;107: 7904-9.
19. Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, Pitari MR, et al. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res 2012;18:6260-70.
20. Grcevic D, Kusec R, Kovacic N, Lukic A, Lukic IK, Ivcevic S, et al. Bone morphogenetic proteins and receptors are over-expressed in bonemarrow cells of multiple myeloma patients and support myeloma cells by inducing ID genes. Leuk Res 2010;34:742-51.
21. Lionetti M, Agnelli L, Mosca L, Fabris S, Andronache A, Todoerti K, et al. Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles. Genes Chromosomes Cancer 2009;48:521-31.
22. Xiong J. Emerging roles of microRNA-22 in human disease and normal physiology. Curr Mol Med 2012;12:247-58.
23. Takata A, Otsuka M, Kojima K, Yoshikawa T, Kishikawa T, Yoshida H, et al. MicroRNA-22 and microRNA-140 suppress NF-kappaB activity by regulating the expression of NF-kappaB coactivators. Biochem Biophys Res Commun 2011;411:826-31.
24. Wu F, Zhu S, Ding Y, Beck WT, Mo YY. MicroRNA-mediated regulation of Ubc9 expression in cancer cells. Clin Cancer Res 2009;15:1550-7.
25. Guo X, Guo L, Ji J, Zhang J, Zhang J, Chen X, et al. miRNA-331-3p directly targets E2F1 and induces growth arrest in human gastric cancer. Biochem Biophys Res Commun 2010;398:1-6.
26. Wang H, Wu J, Meng X, Ying X, Zuo Y, Liu R, et al. MicroRNA-342 inhibits colorectal cancer cell proliferation and invasion by directly targeting DNA methyltransferase 1. Carcinogenesis 2011;32:1033-42.
27. Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, Azab F, et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 2009;113:6669-80.
28. Hao M, Zhang L, An G, Meng H, Han Y, Xie Z, et al. Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leuk Lymphoma 2011;52:1787-94.
29. Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A 2008;105:12885-90.
30. Chen L, Li C, Zhang R, Gao X, Qu X, Zhao M, et al. miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma. Cancer Lett 2011;309:62-70.
31. Faraoni I, Antonetti FR, Cardone J, Bonmassar E. miR-155 gene: a typical multifunctional microRNA. Biochim Biophys Acta 2009;1792: 497-505.
32. Tili E, Croce CM, Michaille JJ. miR-155: on the crosstalk between inflammation and cancer. Int Rev Immunol 2009;28:264-84.
33. Loffler D, Brocke-Heidrich K, Pfeifer G, Stocsits C, Hackermuller J, Kretzschmar AK, et al. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of micro-RNA-21 through a highly conserved enhancer. Blood 2007;110: 1330-3.
34. Leone E, Morelli E, Di Martino MT, Amodio N, Foresta U, Gulla' A, et al. Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res 2013;19:2096-106.
35. Olive V, Jiang I, He L. mir-17-92, a cluster of miRNAs in the midst of the cancer network. Int J Biochem Cell Biol 2010;42:1348-54.
36. Pan J, Hu H, Zhou Z, Sun L, Peng L, Yu L, et al. Tumor-suppressive mir-663 gene induces mitotic catastrophe growth arrest in human gastric cancer cells. Oncol Rep 2010;24:105-12.
37. Tili E, Michaille JJ, Adair B, Alder H, Limagne E, Taccioli C, et al. Resveratrol decreases the levels of miR-155 by upregulating miR-663, amicroRNA targeting Jun B and Jun D. Carcinogenesis 2010;31: 1561-6.
38. Xu C, Liu S, Fu H, Li S, Tie Y, Zhu J, et al. MicroRNA-193b regulates proliferation, migration and invasion in human hepatocellular carcinoma cells. Eur J Cancer 2010;46:2828-36.
39. Chen J, Feilotter HE, Pare GC, Zhang X, Pemberton JG, Garady C, et al. MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am J Pathol 2010;176:2520-9.
40. Li XF, Yan PJ, Shao ZM. Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer. Oncogene 2009;28:3937-48.
41. Meister J, Schmidt MH. miR-126 and miR-126: new players in cancer. Scientific World Journal 2010;10:2090-100.
42. Boyerinas B, Park SM, Hau A, Murmann AE, Peter ME. The role of let-7 in cell differentiation and cancer. Endocr Relat Cancer 2010;17: F19-F36.
43. Meng F, Henson R, Wehbe-Janek H, Smith H, Ueno Y, Patel T. The MicroRNA let-7a modulates interleukin-6-dependent STAT-3 survival signaling in malignant human cholangiocytes. J Biol Chem 2007;282: 8256-64.
44. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NFkappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009;139:693-706.
45. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 2010;39:493-506.
46. Sheedy FJ, Palsson-McDermott E, Hennessy EJ, Martin C, O'Leary JJ, Ruan Q, et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol 2010;11:141-7.
47. Ma X, Becker Buscaglia LE, Barker JR, Li Y. MicroRNAs in NF-kappaB signaling. J Mol Cell Biol 2011;3:159-66.
48. Li Y, Li W, Yang Y, Lu Y, He C, Hu G, et al. MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. Brain Res 2009;1286:13-8.
49. Yu SC, Chen SU, Lu W, Liu TY, Lin CW. Expression of CD19 and lack of miR-223 distinguish extramedullary plasmacytoma from multiple myeloma. Histopathology 2011;58:896-905.
50. Jia CY, Li HH, Zhu XC, Dong YW, Fu D, Zhao QL, et al. MiR-223 suppresses cell proliferation by targeting IGF-1R. PLoS One 2011;6: e27008.
51. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer 2012;12:335-48. Ricerca